| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Mannan does not have a defined pharmacological target. It is a polysaccharide that functions as a pathogen-associated molecular pattern (PAMP) recognized by immune system receptors such as the mannose receptor and dectin-2. Its mechanism of action involves binding to these receptors on immune cells, leading to activation of innate immune responses, including phagocytosis and cytokine production.
|
|---|---|
| ln Vitro |
In vitro, mannan is used as a biochemical reagent and research tool. It is used to study nonopsonic uptake of Mycobacterium avium complex by human monocytes and alveolar macrophages. The compound is also used to investigate new lectins from plants, such as from bulbs of Croccus sativum. As a polysaccharide, it serves as a model compound for studying carbohydrate-protein interactions and immune recognition.
|
| ln Vivo |
In vivo data for mannan as a therapeutic agent are not available, as the compound is a biochemical reagent used for in vitro research. It is not intended for in vivo administration and has no established in vivo pharmacokinetic or pharmacodynamic profile. The compound is not designed for therapeutic use.
|
| Enzyme Assay |
For in vitro immune activation assays, mannan is used to study macrophage and monocyte function. Cells such as human monocytes or alveolar macrophages are treated with mannan at various concentrations (typically 1-100 µg/mL) for 6-24 hours. Phagocytic activity is assessed by measuring uptake of fluorescently labeled particles or bacteria. Cytokine production (e.g., TNF-α, IL-6) is measured by ELISA. The compound's recognition by mannose receptor and dectin-2 can be studied using receptor blocking antibodies.
|
| Cell Assay |
For in vitro cell-based experiments, mannan is used to study lectin-carbohydrate interactions. The compound is used as a ligand in binding assays to identify and characterize new lectins from plant or animal sources. Binding affinity and specificity are assessed using techniques such as surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC). The compound's effects on cell function are assessed using standard cell viability and proliferation assays.
|
| Animal Protocol |
In vivo animal studies for mannan are not applicable, as the compound is a biochemical reagent used for in vitro research. No animal studies have been conducted for this compound as a therapeutic agent, and it is not intended for diagnostic or therapeutic use in animals or humans.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for mannan are not available, as the compound is not a drug and is not administered to living organisms. As a high molecular weight polysaccharide, it is not significantly absorbed from the gastrointestinal tract. The compound is primarily used as a reagent rather than as a drug candidate.
|
| Toxicity/Toxicokinetics |
Toxicity Summary
It is safe at the current usage and concentration. Ingredient, concentration, and usage information can be found at: https://cir-reports.cir-safety.org Mannan is generally considered to be biocompatible and non-toxic. It is a naturally occurring polysaccharide found in yeast and other organisms. The compound is not classified as hazardous under standard GHS criteria. However, standard laboratory safety practices should be followed when handling the compound. The compound is for research use only and not for human therapeutic applications as a drug. |
| Additional Infomation |
It has been reported that aloe vera (Aloe maculata), sea pelt (Hyphaene thebaica), and konjac (Amorphophallus konjac) contain mannan, and relevant data is available. Mannan is a polysaccharide composed of mannose units.
Mannan (from Saccharomyces cerevisiae) (CAS 9036-88-8) is primarily a research-grade biochemical reagent, not an FDA-approved pharmaceutical drug. Its primary applications are in immunology research for studying macrophage function and phagocytosis, in lectin research for studying carbohydrate-protein interactions, and as a model polysaccharide for carbohydrate chemistry. No clinical trials or approved therapeutic indications exist for this compound. |
| Molecular Formula |
H5*N3
|
|---|---|
| Molecular Weight |
47.0598
|
| Exact Mass |
666.221
|
| CAS # |
9036-88-8
|
| PubChem CID |
25147451
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.8±0.1 g/cm3
|
| Boiling Point |
1030.9±65.0 °C at 760 mmHg
|
| Flash Point |
577.3±34.3 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.687
|
| LogP |
-5.83
|
| Hydrogen Bond Donor Count |
14
|
| Hydrogen Bond Acceptor Count |
21
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
45
|
| Complexity |
918
|
| Defined Atom Stereocenter Count |
20
|
| SMILES |
C([C@@H]1[C@H]([C@@H]([C@@H]([C@@H](O1)O[C@@H]2[C@H](O[C@H]([C@@H]([C@H]2O)O)O[C@@H]3[C@H](O[C@H]([C@H]([C@H]3O)O)O[C@H]4[C@H](O[C@H]([C@H]([C@H]4O)O)O)CO)CO)CO)O)O)O)O
|
| InChi Key |
LUEWUZLMQUOBSB-GFVSVBBRSA-N
|
| InChi Code |
InChI=1S/C24H42O21/c25-1-5-9(29)10(30)15(35)22(40-5)44-19-7(3-27)42-24(17(37)12(19)32)45-20-8(4-28)41-23(16(36)13(20)33)43-18-6(2-26)39-21(38)14(34)11(18)31/h5-38H,1-4H2/t5-,6-,7-,8-,9-,10+,11-,12-,13-,14+,15+,16+,17-,18+,19-,20-,21-,22+,23+,24+/m1/s1
|
| Chemical Name |
(2S,3S,4S,5S,6R)-2-[(2R,3S,4R,5R,6S)-6-[(2R,3S,4R,5S,6S)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2R,3R,4R,5S,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 50 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 21.2495 mL | 106.2473 mL | 212.4947 mL | |
| 5 mM | 4.2499 mL | 21.2495 mL | 42.4989 mL | |
| 10 mM | 2.1249 mL | 10.6247 mL | 21.2495 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
